Danish Registry Analysis Finds Consistent Safety After Switching to Infliximab Biosimilar GP1111

February 03, 2026

New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis.

Q&A With Chelsee Jensen, PharmD: FDA Policy Shifts, Biosimilar Development Hurdles, and Market Access in 2026

February 02, 2026

Early Evidence Supports KM118 as a Biosimilar to Reference Pertuzumab

January 28, 2026

Milestone Approvals, Evolving PBM Models May Redefine the 2026 Biosimilar Landscape

January 27, 2026

FDA Draft Guidance on Biosimilars Is a Win for Patients; Now Congress Must Finish the Job

January 26, 2026

Biosimilars Development Roundup for October 2024—Podcast Edition

November 3rd 2024

By Skylar Jeremias

Podcast

On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.

The Top 5 Biosimilar Articles for the Week of October 28

November 2nd 2024

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of October 28, 2024.

Making the Cost of IBD Care Sustainable

November 2nd 2024

By Deana Ferreri, PhD

Article

Panelists Stress Stakeholder Education to Build Confidence in Biosimilars

October 31st 2024

By Skylar Jeremias

Article

By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.

Biosimilars Development Roundup: October 2024

October 31st 2024

By Skylar Jeremias

Article

In October, the GRx+Biosims conference included discussions on data transparency, artificial intelligence, and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.

Enhancing Adoption of Infused Biosimilars for a Sustainable Future

October 30th 2024

By Skylar Jeremias

Article

An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.

Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry

October 29th 2024

By Skylar Jeremias

Article

Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.

How Policy Reforms in PBM Systems Could Change the Adalimumab Market

October 28th 2024

By Skylar Jeremias

Article

Panelists emphasized the need for transparency and policy reforms in pharmacy benefit management (PBM) to improve accessibility, affordability, and fair competition for adalimumab biosimilars.

Veterans’ Experience With Infliximab Biosimilars for IBD Treatment

October 26th 2024

By Deana Ferreri, PhD

Article

A study of the Veterans Health Administration detailed their experience with infliximab biosimilars in a population of patients with inflammatory bowel disease (IBD) who were naive to infliximab.

Strengthening the Supply Chain: Key Insights From FDA Commissioner Dr Robert Califf

October 25th 2024

By Skylar Jeremias

Article

At the GRx+Biosims conference, FDA Commissioner Robert Califf, MD, stressed the urgent need for data transparency in the global supply chain and the role of collaboration and artificial intelligence in ensuring the resilience of biosimilar and generic drug production.